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Chronic granulomatous disease (CGD) is the most common inherited disorder of phagocytic functions, caused by genetic
defects in the leukocyte nicotinamide dinucleotide phosphate (NADPH) oxidase. Consequently, CGD phagocytes are impaired
in destroying phagocytosed microorganisms, rendering the patients susceptible to bacterial and fungal infections. Besides this
immunodeﬁciency, CGD patients suﬀer from various autoinﬂammatory symptoms, such as granuloma formation in the skin
or urinary tract and Crohn-like colitis. Owing to improved antimicrobial treatment strategies, the majority of CGD patients
reaches adulthood, yet the autoinﬂammatory manifestations become more prominent by lack of causative treatment options. The
underlying pathomechanisms driving hyperinﬂammatory reactions in CGD are poorly understood, but recent studies implicate
reducedneutrophilapoptosisandeﬀerocytosis,dysbalancedinnateimmunereceptors,alteredT-cellsurfaceredoxlevels,induction
of Th17 cells, the enzyme indolamine-2,3-dioxygenase (IDO), impaired Nrf2 activity, and inﬂammasome activation. Here we
discuss immunological mechanisms of hyperinﬂammation and their potential therapeutic implications in CGD.
1. ChronicGranulomatousDisease
Chronic granulomatous disease (CGD) is the most common
inherited disorder of phagocytic functions, caused by genetic
defects in the leukocyte nicotinamide dinucleotide phos-
phate (NADPH) oxidase. Phagocytes of CGD patients are
unable to kill ingested microorganisms through reactive oxy-
gen species (ROS), resulting in an augmented susceptibility
of the patients to bacterial and fungal infections [1, 2]. Most
CGD patients are known to suﬀer from recurrent infections
from the ﬁrst year of life. To prevent severe life-threatening
infections, these patients require prophylactic antibiotics
and antimycotics [2, 3]. Bone marrow transplantation is
considered curative, and gene therapy approaches have also
beenimplementedtoovercomesevereinfectionsinCGD[4–
8]. In addition to their impaired antibacterial and antifungal
innate host defense, CGD patients frequently present with
autoimmune phenomena, such as granuloma formation,
Crohn-like disease, pulmonary ﬁbrosis, or others, suggesting
a dysbalanced uncontrolled inﬂammatory response in CGD
[3]. Today, most of the CGD patients reach adulthood
due to improved treatment options for the bacterial and
fungal infections, yet the autoinﬂammatory manifestations
become more prominent. The severe recurrent infections
can be explained by the lack of ROS required for the
killing of pathogens, whereas the underlying reasons for the
hyperinﬂammatory reactions in CGD remain poorly under-
stood, and causative therapy for CGD hyperinﬂammation is
lacking.
2. Inﬂammation in Chronic
GranulomatousDisease
Several lines of evidence support the concept that CGD fea-
tures hyperinﬂammation [9]. Notably, microarray analysis
in neutrophils from CGD patients has revealed upregulation2 Clinical and Developmental Immunology
of several proinﬂammatory genes [10]. Upon stimulation
with TLR2 or TLR4 ligands, leukocytes from CGD patients
yieldanincreasedproductionofproinﬂammatorycytokines,
which is, surprisingly, independent of NADPH oxidase
activity [11].
2.1. Neutrophil Apoptosis and Eﬀerocytosis. Apoptosis (pro-
grammed cell death) of inﬂammatory cells represents a
physiological mechanism to prevent secondary uncontrolled
necrosis and hyperinﬂammation followed by tissue dam-
age. Apoptotic cells externalize phosphatidylserine (PS),
which is recognized through PS-receptors. This interaction
enables the uptake of apoptotic cells by phagocytes (for
instance, macrophages), a process termed “eﬀerocytosis’’
[12]. This controlled removal of apoptotic cells is of pivotal
relevance for short-lived inﬂammatory cells, prototypically
neutrophils. Eﬀerocytosis leads to the secretion of the anti-
inﬂammatory cytokine TGF-β by macrophages and thereby
facilitates resolution of acute inﬂammation [13]. Both apop-
tosisandeﬀerocytosisofapoptoticcellsbymacrophageshave
been reported to be impaired in CGD patients and/or mice
(see Figure 1 for illustration). Constitutive apoptosis has
been shown to be delayed in both human and murine CGD
neutrophils due to impaired PS exposure. This may lead to
unbalanced neutrophil necrosis with release of intracellular
proteases/oxidants and an increased risk of developing lupus
disease in CGD patients [14]. However, other groups could
not determine any signiﬁcant impairment of apoptosis in
CGD monocytes [15] or neutrophils [16]. The latter group
also observed higher rates of necrosis induced by speciﬁc
bacteria in CGD neutrophils [16].
Besides apoptosis, also uptake/eﬀerocytosis of apoptotic
neutrophils has been shown to be impaired by murine CGD
macrophages and has recently been shown to contribute to
hyperinﬂammation in mice [17–19]. Two distinct mecha-
nisms have been reported that play a role in the impaired
r e m o v a lo fa p o p t o t i cc e l l sb ym a c r o p h a g e s( F i g u r e1).
Fernandez-Boyanapallietal.demonstratedthattheimpaired
phagocytosis of apoptotic cells by CGD macrophages could
be reversed by IFN-γ treatment [18]. Further studies showed
that the IFN-γ priming rescue eﬀect was mediated through
NO production, endogenous TNF-α production, and Rac
activation.
Following up the consequences of the deﬁcient PS
exposure in CGD neutrophils, studies demonstrated that the
impaired PS/PSR-dependent production of IL-4 resulted in
reduced generation of 12/15-lipoxygenase and reduced acti-
vation of the transcription factor PPARgamma (peroxisome
proliferator-activated receptor gamma) [17]. This leads to
altered macrophage programming (M2 macrophage phe-
notype) and decreased eﬀerocytosis in CGD macrophages.
The authors showed that it was possible to overcome this
IL-4-dependent defect in eﬀerocytosis by injecting PS in
CGD mouse models in vivo. However, the authors of these
studies also discuss that the impaired clearance of apoptotic
cells, observed in X-CGD, may not be contributable to the
NADPH oxidase deﬁciency, but could be favoured by the
cytokine microenvironment.
2.2. Innate Immune Receptors. Neutrophils are the key eﬀec-
tor cells in antibacterial host defense and are in the focus of
CGD research [20–23]. Eﬀector functionality of neutrophils
is orchestrated by innate immune receptors such as Toll-
like receptors (TLRs) and complement receptors [21–23].
Neutrophils from CGD patients show lower expression levels
ofTLR5,TLR9,CD11b,CD18,CD35,andCXCR1compared
with those from healthy control subjects, whereas similar
or increased receptor expressions are found in patients with
bacterialpneumonia[24].ReducedTLR5expressionresulted
in impaired neutrophil activation by bacterial ﬂagella, and
reducedCD11b/CD18expressionisassociatedwithimpaired
phagocytosis of Staphylococcus aureus.
TLR5 and CD18 expression levels correlate with disease
severity in CGD patients. TLR5 and TLR9 expressions are
higher in patients with residual NADPH oxidase activity. In
vitroinhibitionoftheNADPHoxidaseincontrolneutrophils
decreases TLR5 and TLR9 expression and impairs TLR5
function. TLR5 expression correlates with the frequency
of lymphadenitis in CGD patients, suggesting a clinically
relevant role for TLR5 dysregulation in the course of CGD.
Previous studies of CGD neutrophils have found a reduced
expression of CD35 on neutrophils from patients with CGD
compared to healthy controls and patients with recurrent
infections [25]. When viewed in combination, these studies
indicate that CGD neutrophils are not only restricted in
terms of NADPH-mediated intracellular oxidative killing,
but display distinct phenotypical and functional abnor-
malities. In particular, TLR5 and TLR9 are impaired in
CGD through a mechanism linked to the deﬁcient ROS
production in these cells. Whether and how this dysbalance
of innate immune receptors on CGD neutrophils contributes
to inﬂammatory manifestations awaits further investigation.
2.3. ROS-Dependent Oxidization of T-Cell Membrane Pro-
teins. Rats and mice with a lower capacity to produce
ROS because of polymorphisms or mutations in the gene
encoding the p47phox protein of the NADPH oxidase
complex are more susceptible to develop severe arthritis
[26, 27]. The lower capacity to produce ROS is associated
with an increased number of reduced thiol groups on
T-cell membrane surfaces. This inﬂuences activation and
proliferation of T cells and the susceptibility to arthritis
development [28]. In a recent study the Holmdahl group
further showed that ROS-deﬁcient macrophages can actually
prime autoreactive T cells and initiate autoimmune arthritis
in a murine model of collagen-induced arthritis [29].
2.4. Th17 Cells. Recently, IL-17-producing eﬀector cells
(Th17 cells and γδ T cells) have been found to be involved
in chronic inﬂammatory processes and several autoimmune
diseases, for example, multiple sclerosis or rheumatoid
arthritis. These highly proinﬂammatory cells are essential for
the defence against pathogens [30, 31]. They are considered
to be counterbalanced by regulatory T cells (Treg) [32]. A
ﬁne-tuned activity of both of these T-cell subsets is crucial
for controlling infections, inﬂammation, autoimmunity, and
malignancies [33, 34]. Evidence supporting a contributionClinical and Developmental Immunology 3
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Figure 1: Impaired apoptosis/eﬀerocytosis underlying hyperinﬂammation in CGD. Apoptotic cells (here shown for neutrophils, PMN)
externalize phosphatidylserine (PS), which is recognized through PS-receptors on macrophages. This interaction enables the uptake of
apoptotic cells by macrophages, a process termed “eﬀerocytosis”. Successful eﬀerocytosis leads to the secretion of the anti-inﬂammatory
cytokine TGF-β by macrophages and thereby facilitates resolution of acute inﬂammation. Due to an impaired externalization of PS by
CGD neutrophils and/or other neutrophil-macrophage interaction mechanisms, both apoptosis and eﬀerocytosis have been described to
be dysfunctional in CGD. This leads to unbalanced neutrophil necrosis with release of intracellular proteases/oxidants and persistence of
(sterile) inﬂammation. Two pathways have recently been proposed to be involved in this impairment: PS/PSR interactions were found to
trigger downstream pathways comprising IL-4 and PPARγ, which are critically involved in the regulation of eﬀerocytosis. Beyond that,
impaired phagocytosis of apoptotic cells by CGD macrophages could be reversed by IFN-γ treatment, an eﬀect that was mediated through
NO production, endogenous TNF-α production, and Rac activation.
of IL-17 in CGD hyperinﬂammation was recently derived
from animal model data [35, 36]. When challenged with
either intratracheal zymosan or LPS, NADPH oxidase-
deﬁcient p47phox
−/− mice and gp91phox
−/− mice develop
exaggerated and progressive lung inﬂammation, augmented
NF-kappaB activation, and elevated downstream proinﬂam-
matory cytokines (TNF-alpha, IL-17, and G-CSF) compared
to wild-type mice [36]. Replacement of functional NADPH
oxidase in bone marrow-derived cells restores the normal
lung inﬂammatory response. Studies in vivo and in iso-
lated macrophages have demonstrated that in the absence
of functional NADPH oxidase, zymosan fails to activate
Nrf2, a key redox-sensitive anti-inﬂammatory regulator.
Consistent with these ﬁndings, zymosan-treated peripheral
blood mononuclear cells from X-linked CGD patients show
impaired Nrf2 activity and increased NF-kappaB activation
[36] (Figure 2).
2.5. Indolamine-2,3-Dioxygenase. In addition to regulatory
cells and their speciﬁc cytokines, immune responses are con-
trolled by the enzyme indolamine-2,3-dioxygenase (IDO).
IDO is required for the catabolism of the aromatic amino
acid L-tryptophan and the generation of L-tryptophan
metabolites. Whereas IDO-dependent metabolites of L-
tryptophan like L-kynurenine are well-known immuno-
suppressive agents [37, 38], L-tryptophan itself or IDO-
independent metabolites of tryptophan have been shown to
activate proinﬂammatory Th17 cells [39]. IDO is primarily
expressed in monocytes and dendritic cells [40]. The impact
of IDO on immune regulation has become evident in the
maternal tolerance to the allogeneic fetal tissue [41], in
several autoimmune disorders like type-1 diabetes, multiple
sclerosis, chronic inﬂammatory bowel disease, rheumatoid
arthritis and systemic lupus erythematodes [37], as well as
in the tolerance against malignant tumors [42]. Presently,
a phase-III clinical trial with synthetic immunomodulatory
tryptophan metabolites is being conducted in multiple
sclerosis patients [43]. IDO function has been reported
to be dependent on superoxides [35, 44], which are not
produced in suitable amounts when the NADPH oxidase
system is deﬁcient as in CGD. IDO deﬁciency could thus be
an important factor for the excessive inﬂammatory reactions
in this disease (Figure 2). Recently, in p47phox
−/− mice a4 Clinical and Developmental Immunology
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Figure 2: Other recently proposed mechanisms of hyperinﬂammation in CGD. Three independent mechanisms leading to hyperinﬂam-
mation with increased numbers of Th17 cells have been recently proposed in CGD: Reduced IDO and Nrf2 activity and increased NLRP3
activation.
pathogenic link between defective NADPH oxidase, reduced
tryptophan catabolism, and IL-17-mediated inﬂammation
[35] hasbeen shown. Afterinfection with Aspergillusfumiga-
tus, these mice develop an enormous inﬂammatory response
with a shift in the γδ Tc e l ls y s t e ma n do v e r p r o d u c t i o n
of IL-17 in comparison to wild-type mice. Furthermore,
the hyperinﬂammatory phenotype of the CGD mice can
be mimicked in wild-type mice by IDO blockade and
abolished by replacement therapy with a natural kynurenine
[35]. In humans, however, two independent studies recently
showed, that monocyte-derived dendritic cells generated
from patients harbouring X-linked and autosomal recessive
forms of CGD, and from healthy controls, produced similar
amounts of the tryptophan metabolite kynurenine upon
activation with lipopolysaccharide and interferon-gamma
[45, 46]. Thus, in humans, ROS apparently are dispensable
for IDO activity and hyperinﬂammation in human CGD
cannot be attributed to disabled IDO activation.
2.6. Inﬂammasome Activation. Some in vitro studies suggest
that ROS are crucial for secretion of IL-1beta via inﬂam-
masome activation [47], whereas mice defective for ROS
and patients with CGD have a proinﬂammatory phenotype.
In three current studies, the activation of the IL-1beta
inﬂammasome in cells from CGD patients was evaluated
[48–50]. In contrast to previous studies using the small
molecule diphenylene iodonium (DPI) as an ROS inhibitor,
these studies did not ﬁnd a decrease in either caspase-1
activation or secretion of IL-1beta and IL-18 in primary
CGD monocytes. Moreover, activation of CGD monocytes
by uric acid crystals induced a 4-fold higher level of IL-
1beta secretion compared with that seen in control mono-
cytes. This increase was not due to increased synthesis of
the IL-1beta precursor. In addition, Western blot analysis
of CGD cells revealed that caspase-1 activation was not
decreased, but rather was increased compared with control
cells [48] (Figure 2). Caspase-1 activation was especially
strong in CGD patients with noninfectious inﬂammatory
conditions. Treatment with IL-1 receptor antagonist reduced
IL-1 production in monocytes ex vivo and during medical
therapy [49]. These recent ﬁndings support the concept
that ROS likely dampen inﬂammasome activation and
identify phagocyte oxidase defective monocytes as a source
of elevated IL-1. This provides new potential therapeutic
options for inﬂammatory conditions associated with CGD.
3. Summary
CGD patients suﬀer from various autoinﬂammatory symp-
toms, such as granuloma formation, Crohn-like colitis, and
lung ﬁbrosis. As the majority of CGD patients reaches
adulthood, autoinﬂammatory manifestations become more
prominent and determine morbidity of many CGD patients.
Here we summarize evidence on mechanisms underlyingClinical and Developmental Immunology 5
hyperinﬂammation in CGD. These include reduced neu-
trophil apoptosis, dysbalanced innate immune receptors,
inductionofTh17cells,impairedNrf2activity,andincreased
inﬂammasome activation. Further studies are required to
determine the clinical relevance of and, in particular, the
therapeutic options for manipulation of these mechanisms
in CGD patients.
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